2023
DOI: 10.15360/1813-9779-2023-5-2328
|View full text |Cite
|
Sign up to set email alerts
|

The Effect of ACE Inhibitors/ARBs Withdrawal on the Risk of Postoperative Complications in Abdominal Surgery

N. V. Trembach,
M. A. Magomedov,
V. G. Krasnov
et al.

Abstract: A significant proportion of patients undergoing non-cardiac surgery receive therapy with angiotensin converting enzyme (ACE) inhibitors/angiotensin II receptor blockers (ARBs), which are usually prescribed for treatment of arterial hypertension and CHF. Current guidelines fail to provide clear consensus on whether it is worth discontinuing ACEi/ARBs before non-cardiac surgery.The aim of this research was to assess the contribution of pre-op ACEi/ARBs withdrawal to the development of postoperative complications… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 35 publications
0
1
0
Order By: Relevance
“…The high percentage of postoperative complications negatively affect patient survival, causing an increase in the volume of research to develop strategies to reduce them [2,3]. Many of these strategies involve the preoperative risk stratification of patients based on metabolic parameters and various biomarkers [4][5][6][7]. Despite numerous cancer studies using metabolomic approaches and promising results, these studies still highlight the heterogeneity of metabolic features and behaviors used by tumor cells that go beyond the simple rewiring of anabolic and catabolic pathways [8].…”
Section: Introductionmentioning
confidence: 99%
“…The high percentage of postoperative complications negatively affect patient survival, causing an increase in the volume of research to develop strategies to reduce them [2,3]. Many of these strategies involve the preoperative risk stratification of patients based on metabolic parameters and various biomarkers [4][5][6][7]. Despite numerous cancer studies using metabolomic approaches and promising results, these studies still highlight the heterogeneity of metabolic features and behaviors used by tumor cells that go beyond the simple rewiring of anabolic and catabolic pathways [8].…”
Section: Introductionmentioning
confidence: 99%